YOLFTbeta
00

Chongqing Pharscin Pharmaceutical Co Ltd

002907 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

13.00CNY-0.39 (-2.91%)

Price History

Full chart

Market Stats

Previous Close13.39
Open13.35
Day Range12.92 – 13.45
52-Week Range11.39 – 18.43
Volume6.12M
Market Cap6.21B
P/E (TTM)82.61
Forward P/E0.00
EPS0.18
Dividend Yield0.52%
Beta-0.20
50-Day Avg14.09
200-Day Avg14.05

About

Chongqing Pharscin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China and internationally. It offers generic drugs, traditional Chinese medicines, and food for special medical purposes in various forms, including tablets, granules, capsules, soft capsules, powders, powder injections, lyophilized powder injections, small-volume injections, chemical raw materials, and traditional Chinese medicine extracts. The company is also involved in the provision of CDMO and CMO services; pharmaceutical technology development services and consulting; wholesale and retail activities; and scientific research and technical services. Its products are used in digestive diseases, central nervous system disorders, and otolaryngology therapeutic areas. The company was incorporated in 1996 and is headquartered in Chongqing, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMs. Xiaoying Liu
  • Employees1.44K
  • HeadquartersNo. 89, Middle Section of Huangshan Avenue, Chongqing, China, 401120, China
  • Websitehttps://www.pharscin.com

Leadership

  • Ms. Xiaoying LiuCEO, GM & Director · b. 1962
  • Ms. Xiaoyan PengAccounting Supervisor & CFO · b. 1975
  • Ms. Ying WangHead of Phramaceutical Sales, Deputy GM & Director · b. 1962
  • Ms. Xue Dan YouDeputy GM, Secretary of the Board & Non-Independent Director · b. 1988
  • Xu JunSecurities Affairs Representative
  • Ge LeiSecurities Affairs Representative

Financials

Income Statement

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue347.37M425.90M469.32M551.67M592.10M703.42M842.06M882.47M846.14M785.18M691.54M774.82M827.14M
Growth (%)-+22.61%+10.19%+17.55%+7.33%+18.80%+19.71%+4.80%-4.12%-7.20%-11.93%+12.04%+6.75%
Cost of Revenue128.59M154.39M178.11M196.92M195.26M230.92M307.46M458.88M400.53M320.55M312.45M332.91M352.47M
Gross Profit218.78M271.52M291.21M354.74M396.83M472.49M534.60M423.59M445.61M464.63M379.10M441.91M474.67M
Gross Margin62.98%63.75%62.05%64.30%67.02%67.17%63.49%48.00%52.66%59.17%54.82%57.03%57.39%
Operating Expense191.19M214.81M217.73M261.11M265.78M314.02M336.34M286.15M342.29M355.80M333.27M348.11M405.05M
Operating Income27.59M56.70M73.48M93.63M131.05M158.47M198.26M137.44M103.31M108.83M45.82M93.80M69.62M
Operating Margin7.94%13.31%15.66%16.97%22.13%22.53%23.54%15.57%12.21%13.86%6.63%12.11%8.42%
EBITDA32.91M88.99M109.20M135.35M154.24M183.75M230.85M201.15M191.41M197.20M125.71M177.96M165.69M
EBITDA Margin9.48%20.89%23.27%24.54%26.05%26.12%27.41%22.79%22.62%25.12%18.18%22.97%20.03%
Net Income28.95M58.75M73.84M95.71M111.99M137.37M169.75M119.19M91.78M98.40M32.70M76.73M65.09M
Net Income Margin8.33%13.80%15.73%17.35%18.91%19.53%20.16%13.51%10.85%12.53%4.73%9.90%7.87%
R&D-8.61M7.01M4.06M8.70M18.22M25.56M48.77M60.03M68.11M78.12M74.77M89.76M
R&D as % of Total Revenue-2.02%1.49%0.74%1.47%2.59%3.04%5.53%7.09%8.67%11.30%9.65%10.85%
Interest Expense4.45M5.21M5.78M2.54M1.07M1.27M9.20M17.21M18.25M14.41M1.01M496.00K139.71K
Interest Expense % of Total Revenue1.28%1.22%1.23%0.46%0.18%0.18%1.09%1.95%2.16%1.84%0.15%0.06%0.02%

Balance Sheet

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets415.35M537.39M539.29M652.32M885.15M1.09B1.64B1.72B1.77B1.87B1.85B1.92B2.03B
Total Liabilities174.39M237.62M173.59M190.91M165.20M264.72M566.67M539.59M505.56M256.28M233.53M257.55M319.97M
Total Equity233.32M292.08M365.71M461.42M719.95M828.91M1.07B1.18B1.27B1.61B1.62B1.66B1.69B
Cash30.91M55.92M54.66M85.21M67.30M243.32M286.80M481.40M429.97M503.53M437.56M456.55M274.34M
Total Debt79.60M93.90M43.00M45.00M17.00M48.70M220.29M247.36M251.12M169.88K139.88K127.56K-
Net Debt48.69M37.98M-11.66M-40.21M-50.30M-194.62M-66.50M-234.04M-178.85M-503.36M-437.28M-456.51M-

Cash Flow

Currency: CNY2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow47.34M20.22M66.10M57.73M81.34M31.80M65.92M113.64M82.85M13.04M219.34M161.77M62.24M
Investing Cash Flow-19.06M-4.30M-16.19M-16.69M-216.69M143.55M-269.67M87.33M-108.54M-5.29M-157.83M-107.21M-
Financing Cash Flow-22.38M-2.72M-49.37M-488.00K117.44M674.36K247.34M-6.09M-25.66M-32.35M-30.23M-35.63M-
Capital Expenditure19.06M13.79M16.20M16.69M41.87M36.30M64.66M46.69M56.64M60.62M92.82M16.15M14.56M
Free Cash Flow28.27M6.43M49.91M41.04M39.47M-4.50M1.25M66.95M26.21M-47.57M126.52M145.62M47.68M
Dividends Paid5.18M5.21M3.52M2.49M1.10M29.61M14.84M19.38M13.40M20.00M30.17M35.50M35.50M
FCF to OCF59.73%31.82%75.50%71.09%48.52%-14.17%1.90%58.91%31.64%-364.69%57.68%90.02%76.61%
Dividend Paid to FCF18.32%81.03%7.06%6.06%2.78%-657.50%1184.44%28.94%51.12%-42.05%23.84%24.38%74.44%

Earnings

Report DateDec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Apr 27, 2020Aug 26, 2020Oct 28, 2020Dec 31, 2020Apr 28, 2021Aug 27, 2021Oct 29, 2021Dec 31, 2021Apr 28, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023May 22, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024May 22, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------------------------
EPS Actual0.050.070.080.120.060.080.150.110.080.070.090.080.060.090.050.080.010.070.060.050.060.070.030.01-0.030.100.020.070.010.100.030.04-0.020.080.07
Surprise-----------------------------------
Timing-----------------Pre-market-------After-hours---After-hours-----

Key Statistics & Ratios

Market Cap6.21B
Enterprise Value5.60B
Trailing P/E82.61
Forward P/E0.00
Price / Sales7.77
Price / Book3.53
EPS0.18
Book Value4.16
Revenue (TTM)798.78M
Gross Profit (TTM)458.32M
EBITDA145.81M
Profit Margin9.28%
Operating Margin13.26%
Return on Equity3.41%
Return on Assets1.72%
Shares Outstanding417.60M
Shares Float126.42M
Beta-0.20
Dividend Yield0.52%
Dividend Rate0.08
Payout Ratio42.25%

Dividends

20262×
0.04Sep 4, 20260.04Jun 4, 2026
20252×
0.04Sep 9, 20250.05May 30, 2025
20242×
0.04Sep 10, 20240.05Jun 4, 2024
20231×
0.07Jun 13, 2023
20221×
0.05Jul 14, 2022
20211×
0.03Jun 24, 2021
20201×
0.04Jul 17, 2020
20191×
0.04Apr 26, 2019
20181×
0.07Jun 22, 2018